联合应用地塞米松、5-羟色胺3受体阻滞剂及神经激肽1受体拮抗剂预防铂类多日化疗相关性恶心呕吐的效果

孙志苹 ,  朱仔丹 ,  张猛

西北药学杂志 ›› 2026, Vol. 41 ›› Issue (5) : 193 -198.

PDF (527KB)
西北药学杂志 ›› 2026, Vol. 41 ›› Issue (5) : 193 -198. DOI: 10.3969/j.issn.1004-2407.2026.05.027
药物与临床

联合应用地塞米松、5-羟色胺3受体阻滞剂及神经激肽1受体拮抗剂预防铂类多日化疗相关性恶心呕吐的效果

作者信息 +

Efficacy of combined application of dexamethasone, 5-hydroxytryptamine 3 receptor antagonists, and neurokinin-1 receptor antagonists in preventing chemotherapy-induced nausea and vomiting associated with multi-day platinum-based chemotherapy

Author information +
文章历史 +
PDF (539K)

摘要

目的 探究联合应用地塞米松、5-羟色胺3受体阻滞剂(5-hydroxytryptamine 3 receptor antagonist,5-HT3 RA)及神经激肽1受体拮抗剂(neurokinin 1 receptor antagonist,NK-1 RA)在预防铂类多日化疗相关性恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)患者中的效果。 方法 前瞻性选取2023年10月至2025年10月于连云港市第一人民医院灌南院区接受铂类多日化疗的102例患者作为研究对象。采用自身对照设计,所有患者均接受3种止吐方案:A组(第一周期d1~d3:地塞米松+5-HT3 RA)、B组(第二周期d1:地塞米松+5-HT3 RA+NK-1 RA;d2~d3同A组)、C组(第三周期d1与d3同B组d1,d2方案同A组)。观察各组CINV情况以及急性期(24 h内)、延迟期(24~120 h)及总时期(0~120 h)的疗效,并比较3组的恶心呕吐生活功能指数量表(Functional Living Index-Emesis,FLIE)评分和不良反应发生率。 结果 急性期、延迟期以及总时期3组的CINV严重程度分级分布差异有统计学意义(P<0.05)。B、C组急性期、延迟期及总时期的完全缓解(complete response,CR)率均高于A组,差异有统计学意义(P<0.05);C组各时期的CR率略高于B组,但差异无统计学意义(P>0.05)。FLIE评分表现为:C组>B组>A组,差异均有统计学意义(P<0.05)。3组不良反应的发生率比较差异无统计学意义(P>0.05)。 结论 联合应用NK-1 RA可提高地塞米松联合5-HT3 RA预防CINV的效果,且未显著增加安全性风险。

Abstract

Objective To analyze the efficacy of combined application of dexamethasone, 5-hydroxytryptamine 3 receptor antagonist (5-HT3 RA), and neurokinin-1 receptor antagonist (NK-1 RA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with multi-day platinum-based chemotherapy. Methods A total of 102 patients who received multi-day platinum-based chemotherapy in Guannan Branch of Lianyungang First People’s Hospital from October 2023 to October 2025 were prospectively enrolled. A self-controlled design was adopted, in which all patients sequentially received 3 antiemetic regimens: Group A (cycle 1, day 1 to day 3: dexamethasone+5-HT3 RA), Group B (cycle 2, day 1: dexamethasone+5-HT3 RA+NK-1 RA; day 2 to day 3: same regimen as Group A), and Group C (cycle 3, day 1 and day 3: same antiemetic regimen as day 1 of Group B; day 2: same regimen as Group A). The incidence of CINV and the efficacy in the acute phase (within 24 hours), delayed phase (24-120 hours), and total phase (0-120 hours) were observed. The Functional Living Index-Emesis (FLIE) scores and the incidence of adverse reactions were compared among the 3 groups. Results Significant differences were observed in the distribution of CINV severity grades among the 3 groups in the acute phase, delayed phase, and total phase (P<0.05). The complete response (CR) rates in the acute phase, delayed phase, and total phase of Groups B and C were higher than those of Group A, with statistically significant differences (P<0.05); the CR rates of Group C in each phase were slightly higher than those of Group B, but the difference was not statistically significant (P>0.05). The FLIE scores showed: Group C>Group B>Group A, with statistically significant differences (P<0.05). There was no significant difference in the incidence of adverse reactions among the 3 groups (P>0.05). Conclusion The combined application of NK-1 RA can improve the efficacy of dexamethasone combined with 5-HT3 RA in preventing CINV, without significantly increasing safety risks.

关键词

化疗相关性恶心呕吐 / 铂类化疗 / 多日 / 地塞米松 / 5-羟色胺3受体阻滞剂 / 神经激肽1受体拮抗剂

Key words

chemotherapy-induced nausea and vomiting / platinum-based chemotherapy / multi-day / dexamethasone / 5-hydroxytryptamine 3 receptor antagonists / neurokinin-1 receptor antagonists

引用本文

引用格式 ▾
孙志苹,朱仔丹,张猛. 联合应用地塞米松、5-羟色胺3受体阻滞剂及神经激肽1受体拮抗剂预防铂类多日化疗相关性恶心呕吐的效果[J]. 西北药学杂志, 2026, 41(5): 193-198 DOI:10.3969/j.issn.1004-2407.2026.05.027

登录浏览全文

4963

注册一个新账户 忘记密码

化疗相关性恶心呕吐(chemotherapy-induced nausea and vomiting,CINV)是肿瘤患者在化疗期间较常见且较痛苦的不良反应,其发生率可达70%~80%[1-2]。在众多化疗药物中,以顺铂为代表的铂类药物因具有高度致吐风险,尤其在多日给药方案中,其引发的恶心呕吐症状往往更为持久和剧烈,已成为临床管理的重点与难点[3-4]。CINV的发生机制复杂,涉及多条神经递质通路,其中5-羟色胺受体(5-hydroxytryptamine 3 receptor,5-HT3 R)与P物质/神经激肽1受体(neurokinin 1 receptor,NK1 R)通路分别介导急性期与延迟期呕吐[5]。因此,联合靶向不同通路的止吐药物已成为当前预防高致吐性化疗所致CINV的核心策略。地塞米松作为基础用药,具有广泛的抗炎及增强其他止吐药效果的作用;5-HT3 RA可有效抑制化疗后急性期由肠道嗜铬细胞释放的5-HT所介导的呕吐反射;而NK1 RA则通过阻断P物质在中枢呕吐中枢的作用,对控制延迟期CINV至关重要[6-8]。然而,现有研究多集中于单日化疗方案,对多日化疗中NK-1 RA的最佳给药时机与频次仍缺乏高质量证据。基于此,本研究通过前瞻性对照研究,评估地塞米松、5-HT3 RA及NK-1 RA三联方案在铂类多日化疗CINV预防中的临床疗效与安全性。

1 一般资料

本研究为前瞻性自身对照研究。选取2023年10月至2025年10月于连云港市第一人民医院灌南院区接受铂类多日化疗的102例患者作为研究对象。根据患者各周期止吐方案的不同分为A组、B组、C组。本研究经连云港市第一人民医院灌南院医区医院医学伦理委员会审核、批准。

纳入标准:经病理确诊为恶性肿瘤;拟接受≥3周期含铂化疗方案的治疗;年龄≥18岁;卡氏评分[9]≥70分;无化疗禁忌证;入组前1周无恶心、呕吐症状;对本研究内容知情,并签署同意书。

排除标准:合并吞咽障碍者;长期服用激素类药物者;处于妊娠期或哺乳期者;合并肠梗阻者;对本研究使用的止吐药物过敏者;未能完成3个周期化疗和止吐治疗者。

2 方法

2.1 治疗方法

入组后患者接受包含顺铂方案25 mg·(m-2·d-1)或者奈达铂30 mg·(m-2·d-1)的三日化疗,以28 d为1个周期,共治疗3个周期。以自身为对照,方案中:5-HT3 RA为帕洛诺司琼注射液(规格为0.25 mg,杭州九源基因工程有限公司)0.25 mg·d-1,于化疗前30 min静脉给药;NK-1 RA为注射用福沙匹坦双葡甲胺(规格为150 mg,正大天晴药业集团股份有限公司)150 mg·d-1,于化疗前30 min静脉给药;地塞米松(规格为1 mL∶5 mg,河南润弘制药股份有限公司)5 mg·d-1,于化疗前30 min静脉给药。所有患者依次接受下述止吐方案,见表1。

2.2 观察指标

2.2.1 主要结局指标

2.2.1.1 CINV的严重程度

观察首次呕吐的发生情况,并对患者急性期(自每周期铂类首次化疗结束后至每周期末次化疗结束后24 h内)、延迟期(每周期铂类末次化疗结束24~120 h)及总时期(每周期铂类首次化疗开始至末次化疗结束后120 h内)CINV的严重程度进行评估[10]:0级,无恶心;Ⅰ级,有恶心;Ⅱ级,暂时性呕吐;Ⅲ级,呕吐需要治疗干预;Ⅳ级,难以控制的呕吐。

2.2.1.2 完全缓解(complete response,CR)率

记录各时期CR的发生情况,其定义为无呕吐且无需解救措施的严重干呕。

2.2.2 次要结局指标

采用恶心呕吐生活功能指数量表(Functional Living Index-Emesis,FLIE)[11]评估各周期CINV对患者生活质量的影响。FLIE量表分为恶心、呕吐两个维度,每个维度包括9个问题,每个问题的分值为1~7分,分值越高表示CINV对患者生活质量的影响越小。

2.2.3 安全性指标

观察并记录患者发生头痛、食欲下降、腹泻、皮疹等不良反应的情况,并根据CTCAE 4.0标准进行分级。

2.3 统计学方法

采用SPSS 26.0软件对数据进行处理。计量资料经Shapiro-Wilk检验服从正态分布,以(x¯±s)表示,多组比较采用单因素方差分析,组内比较采用配对样本t检验。计数资料以“例(%)”表示,比较行χ2检验,等级资料比较采用Wilcoxon符号秩和检验(两两比较)或Friedman秩和检验(多组比较),采用Bonferroni进行校正,校正后的检验水准α’=0.05/比较次数。P<0.05为差异有统计学意义。

3 结果

3.1 患者的一般资料

本研究共纳入102例患者,年龄为27~78岁,平均(56.27±8.34) 岁,其中男58例,女44例,肿瘤类型以消化系肿瘤(38.24%)为主。102例患者均按计划完成了3个周期的化疗和止吐治疗,无病例脱落。见表2。

3.2 各时期CINV严重程度的比较

急性期、延迟期以及总时期3组的CINV严重程度分级分布差异有统计学意义(P<0.05);两两比较结果显示,各时期B、C组与A组的分级分布差异均有统计学意义(P<0.05),B、C组比较差异无统计学意义(P>0.05)。见表3。

3.3 各时期CINV CR率的比较

B、C组急性期、延迟期及总时期的CR率均高于A组,差异均有统计学意义(P<0.05);C组各时期的CR率均略高于B组,但2组比较差异无统计学意义(P>0.05)。见表4。

3.4 生活质量的比较

各周期恶心、呕吐及FLIE总分表现为:C组>B组>A组,且两两比较,差异均有统计学意义(P<0.05)。见表5。

3.5 不良反应发生率的比较

A组的不良反应总发生率为24.51%(25/102),B组为26.47%(27/102),C组为29.41%(30/102),3组不良反应发生率比较差异无统计学意义(P>0.05)。所有不良反应严重程度均较轻,均为1~2级,主要表现为轻微头痛、食欲下降、一过性腹泻等,均在24~48 h内自行缓解或经对症处理后好转,未出现3级及以上严重不良反应,无因不良反应导致的治疗中断或剂量调整。见表6。

4 讨论

化疗是当前恶性肿瘤综合治疗的基石性手段[12-13],CINV作为其较常见的不良反应,严重影响患者的治疗依从性和生活质量[14-15]。据统计,超过70%的化疗患者在延迟期会出现不同程度的CINV,影响其治疗进程和效果[16-17]。多日化疗由于药物暴露时间延长,故CINV的发生机制更为复杂,其临床防控难度显著高于单日化疗。尽管国内共识[18]将5-HT3RA联合地塞米松作为多日化疗CINV全程预防的基础止吐方案,但仍存在延迟性CINV未获完全缓解的情况,成为临床亟待解决的问题。

近年来,NK-1RA的问世为CINV防控带来了新突破,该类药物通过高选择性阻断中枢神经系统中P物质与NK-1RA的结合,在延迟性CINV的预防中表现出独特优势[19]。本研究结果显示,在急性期、延迟期及总时期,含NK-1 RA的升级方案(B组与C组)在CR率和CINV严重程度分级分布上均显著优于传统双联方案(A组)。地塞米松联合5-HT3 RA作为经典的双联方案,主要作用于5-HT通路,对急性期CINV有良好的预防作用,但对由P物质介导的延迟期CINV控制力有限[20]。CR率是衡量止吐方案效果的金标准之一,B、C组的CR率显著提升,表明在化疗首日加入NK-1 RA构成三联方案,可帮助更多患者实现全程无恶心呕吐的治疗目标,且各时期CINV严重程度均得到显著改善。上述临床结局进一步支持NK-1 RA通过阻断中枢P物质与NK-1受体结合,抑制由P物质介导的致吐通路,从而在CINV预防中发挥重要作用,与既往研究的结果一致[21]。值得注意的是,两种升级方案(B组与C组)在上述两项关键指标上均未显示出统计学差异。这一结果表明对于本研究涉及的具体化疗方案,在化疗首日单次使用NK-1 RA所提供的保护,在达到CR这一最高治疗目标方面,可能与多日给药方案效果相当。从药理学机制方面分析,福沙匹坦作为前体药物,在体内可迅速转化为阿瑞匹坦,其半衰期长达9~13 h,对NK-1受体的抑制作用可持续48 h以上。因此,对于为期3 d的化疗方案,第1日单次给药已能覆盖后续的延迟期,这可能是B组与C组CR率无显著差异的药理学基础。但不能完全排除是受本研究样本量所限,对微小差异的检测效能不足。此外,等效性可能高度依赖于化疗方案的具体致吐风险谱和药物代谢动力学[22],对于某些致吐风险极高或具有特定药代动力学特性的方案,多日给药依然存在一定的必要性。

本研究通过比较3组的生活质量发现,各周期恶心、呕吐及FLIE总分表现为:C组>B组>A组,且差异均具有统计学意义,表明C组的方案在改善恶心呕吐对患者日常生活功能影响方面,显著优于B组和A组方案。这一结果表明,追加d3的NK-1 RA给药,可能通过更持久地稳定中枢P物质通路,能更有效地抑制恶心这一主观症状,而其改善程度是单纯缓解呕吐无法充分体现的,从而带来了患者体验层面的显著提升。表明CR率作为主要终点可能对恶心这一主观且困扰患者的症状不够敏感,联合FLIE等功能性指标可更全面地评估止吐治疗的综合获益。此外,3组不良反应发生率比较差异无统计学意义,表明在地塞米松联合5-HT3 RA的基础上,加用NK-RA并未显著增加安全性风险。

本研究存在一定的局限性:首先,样本量相对有限,可能影响对2组升级方案间微小差异的检测效能;其次,观察周期仅为3个连续化疗周期,无法完全排除周期累积效应或患者预期心理对报告的潜在影响。未来研究可通过更大样本、随机交叉设计,并纳入救援药物使用量、成本-效用分析等终点,进一步验证本研究的结论。

综上所述,对于接受多日化疗的肿瘤患者,在标准双联止吐方案的基础上,联合使用NK-1 RA能降低CINV的严重程度,提升临床疗效和生活质量,且未显著增加安全性风险。临床可根据患者对生活质量的追求程度及经济考量,个体化选择适合的止吐方案。

参考文献

[1]

聂吴仪,周娟,程东海,等.神经激肽1受体拮抗剂替代地塞米松二联方案预防中度致吐风险化疗所致恶心呕吐的随机对照试验[J].海军军医大学学报,2024,45(4):462-469.

[2]

Nie Wuyi, Zhou Juan, Cheng Donghai,et al. Neurokinin-1 receptor antagonist as an alternative to dexamethasone in standard dual regimen for moderately emetogenic chemotherapy-induced nausea and vomiting:A randomized controlled trial[J]. Academic Journal of Naval Medical University,2024,45(4):462-469.

[3]

Bakhshi S, Kn S, Ganguly S,et al. Extended aprepitant in control of delayed Emesis during induction chemotherapy for acute myeloid leukaemia-an multicentric,investigator-initiated,open label randomized controlled trial[J]. Blood,2025,146:1681.

[4]

Zhang L, Chen M, Zhou Q,et al. Olanzapine combined with standard antiemetics for the prevention of nausea and vomiting in patients with germ cell tumor undergoing a 5-day cisplatin-based chemotherapy (NAVIGATE study):A phase Ⅲ crossover trial[J]. Eur J Cancer,2025,222:115437.

[5]

Garcia Leon J L, DiCristina C, Yao R,et al.Safety and tolerability of a 3-day fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients:Results of an open-label,single-arm phase 4 trial[J]. Pediatr Hematol Oncol,2025,42(2):79-91.

[6]

Gao A, Guan S, Sun Y,et al.Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy[J].BMC Cancer,2023,23(1):609.

[7]

He Y, Lou F, Huang X,et al .Efficacy of single low-dose dexamethasone with NEPA for the 168 h prevention of highly or moderately emetogenic chemotherapy[J]. Front Pharmacol,2025,16:1622789.

[8]

孙琳,李岳洁,张静,等.艾司氯胺酮联合舒芬太尼+昂丹司琼全身麻醉对结直肠癌根治术患者镇痛效果、应激指标及术后恢复的影响[J].分子诊断与治疗杂志,2025,17(6):1077-1080.

[9]

Sun Lin, Li Yuejie, Zhang Jing,et al. Effects of esketamine combined with sufentanil+ondansetron general anesthesia on anal-gesia,stress indexes and postoperative recovery in patients with colorectal cancer undergoing radical surgery[J].Journal of Molecular Diagnosis and Therapy,2025,17(6):1077-1080.

[10]

李薇,谢鹏,王敏.阿瑞匹坦过饱和自乳化颗粒剂的制备与体内外评价[J].西北药学杂志,2025,40(6):101-109.

[11]

Li Wei, Xie Peng, Wang Min.Preparation and in vivo evaluation of aprepitant supersaturated self-emulsifying drug delivery system granules[J].Northwest Pharmaceutical Journal,2025,40(6):101-109.

[12]

Mercadante S, Grassi Y, Lo Cascio A,et al.Symptom burden poorly responsive to palliative care intervention and karnofsky predict survival in an acute palliative care unit[J]. Cancers,2025,17(10):1704.

[13]

赵中亭,王小花,曹洁,等.药物铺灸辅助治疗胃癌脾胃虚寒型化疗相关性恶心呕吐:随机对照试验[J].中国针灸,2025,45(12):1723-1729.

[14]

Zhao Zhongting, Wang Xiaohua, Cao Jie,et al.Herb-spreading moxibustion as an adjuvant treatment for chemotherapy-induced nausea and vomiting of spleen and stomach deficiency cold in gastric cancer:A randomized controlled trial[J]. Chinese Acupuncture & Moxibustion,2025,45(12):1723-1729.

[15]

Fan T, Luo C.Minimal clinically important difference of the Functional Living Index-Emesis in patients with gynecological malignant tumor:A post hoc analysis of a single-arm study[J].J Obstet Gynaecol Res,2023,49(11):2711-2716.

[16]

张雪,王兴霞,付玲玲,等.TC方案联合贝伐珠单抗治疗晚期上皮性卵巢癌的临床疗效及对miRNA-21和CA125的影响[J].中南医学科学杂志,2025,53(3):466-469.

[17]

Zhang Xue, Wang Xingxia, Fu Lingling,et al.Clinical efficacy of TC regimen combined with bevacizumab in the treatment of advanced epithelial ovarian cancer and its impact on miRNA-21 and CA125[J].Medical Science Journal of Central South China,2025,53(3):466-469.

[18]

武洁,曹利美,刘雨溦,等.胃癌化疗病人癌因性疲乏现状及影响因素[J].护理研究,2025,39(13):2278-2285.

[19]

Wu Jie, Cao Limei, Liu Yuwei,et al.Current status and influencing factors of cancer-related fatigue in patients with gastric cancer undergoing chemotherapy[J].Chinese Nursing Research,2025,39(13):2278-2285.

[20]

魏浩洁,武东,黄灿,等.乳腺癌患者化疗所致恶心呕吐预防失败的危险因素分析与预测模型建立[J].中国医院药学杂志,2024,44(23):2761-2767.

[21]

Wei Haojie, Wu Dong, Huang Can,et al.Risk factors and prediction modeling for prevention failure of chemotherapy-related nausea and vomiting in breast cancer patients[J]. Chinese Journal of Hospital Pharmacy,2024,44(23):2761-2767.

[22]

张旭,高秀容,王芊入,等.抗呕吐药5-HT3受体拮抗剂的经皮给药制剂研究进展[J].中国药学杂志,2024,59(17):1590-1596.

[23]

Zhang Xu, Gao Xiurong, Wang Qianru,et al.Research progress of transdermal delivery of anti-vomiting drug 5-HT3 receptor antagonist[J].Chinese Pharmaceutical Journal,2024,59(17):1590-1596.

[24]

Belluomini L, Avancini A, Sposito M,et al.Integrating nutrition,physical exercise,psychosocial support and antiemetic drugs into CINV management:The road to success[J]. Crit Rev Oncol,2024,201:104444.

[25]

Navari R, Binder G, Molasiotis A,et al.Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles[J]. Oncologist,2023,28(3):208-213.

[26]

肖彩芝,王维,夏冬琴,等.化疗所致恶心呕吐中西医诊治专家共识[J].中国医院用药评价与分析,2023,23(12):1409-1415,1421.

[27]

Xiao Caizhi, Wang Wei, Xia Dongqin,et al.Expert consensus on diagnosis and treatment of chemotherapy-induced nausea and vomiting in traditional Chinese medicine and western medicine[J]. Evaluation and Analysis of Drug-Use in Hospitals of China,2023,23(12):1409-1415,1421.

[28]

于丽婷,王卓,周芬,等.神经激肽1受体拮抗剂预防肿瘤患儿高致吐化疗药物相关恶心呕吐的有效性和安全性评估[J].临床儿科杂志,2022,40(1):34-39.

[29]

Yu Liting, Wang Zhuo, Zhou Fen,et al.Efficacy and safety of neurokinin 1 receptor antagonists for the prevention of highly emetogenic chemotherapy-related nausea and vomiting in pediatric patients with cancer[J].Journal of Clinical Pediatrics,2022,40(1):34-39.

[30]

丁洁,王娟,王莉,等.福沙匹坦预防含顺铂化疗引起恶心呕吐的疗效及安全性[J].现代肿瘤医学,2021,29(5):868-871.

[31]

Ding Jie, Wang Juan, Wang Li,et al. Efficacy and safety of fosaprepitant in patient with nausea and vomiting caused by chemotherapy[J]. Journal of Modern Oncology,2021,29(5):868-871.

[32]

Zhang Y, Luo X, Fan Q,et al.Efficacy of fosaprepitant for the prevention of postoperative nausea and vomiting in patients undergoing gynecologic surgery:A multicenter,randomized,double-blind study[J].Anesthesiol Perioper Sci,2024,2(4):40.

[33]

An Y, Zhang Z, Gu M,et al.Low dose olanzapine in the prevention and treatment of carboplatin Induced Nausea and vomiting:A prospective clinical randomized controlled trial[J]. CPD,2023,29(23):1867-1874.

基金资助

连云港市卫生科技项目(QN202313)

AI Summary AI Mindmap
PDF (527KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉